Shanghai Medicilon (SHSE:688202) Accounts Payable: ¥231 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688202 Shanghai Medicilon Inc SHSE:688202
72 GF Score
Price ¥95.10
GF Value ¥45.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Shanghai Medicilon Accounts Payable?

Shanghai Medicilon SHSE:688202 +16.26% 72 Accounts Payable is ¥231 Mil as of Mar. 2026. GuruFocus rates SHSE:688202 with a GF Score™ of 72/100 and a GF Value™ of ¥45.37 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shanghai Medicilon's Accounts Payable for the quarter that ended in Mar. 2026 was ¥231 Mil.

Shanghai Medicilon's quarterly Accounts Payable increased from Sep. 2025 (¥161 Mil) to Dec. 2025 (¥176 Mil) and increased from Dec. 2025 (¥176 Mil) to Mar. 2026 (¥231 Mil).

Shanghai Medicilon's annual Accounts Payable declined from Dec. 2023 (¥190 Mil) to Dec. 2024 (¥145 Mil) but then increased from Dec. 2024 (¥145 Mil) to Dec. 2025 (¥176 Mil).

Shanghai Medicilon Accounts Payable Related Terms

Shanghai Medicilon Accounts Payable Historical Data

* Premium members only.

The historical data trend for Shanghai Medicilon's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Medicilon Accounts Payable Chart

Shanghai Medicilon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.10 218.30 190.24 144.51 175.80

Shanghai Medicilon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.14 126.95 161.47 175.80 230.68
SHSE:688202
72GF Score
Shanghai Medicilon Inc SHSE:688202
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Medicilon Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥231 Mil mean?
Shanghai Medicilon (SHSE:688202) has a Accounts Payable of ¥231 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Shanghai Medicilon and its competitors.
Is Shanghai Medicilon's Accounts Payable too high?
Shanghai Medicilon's current Accounts Payable is ¥231 Mil. Overall, Shanghai Medicilon has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Accounts Payable compare to VRTX and REGN?
Shanghai Medicilon's Accounts Payable of ¥231 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Shanghai Medicilon and its competitors. Shanghai Medicilon's current Accounts Payable is ¥231 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.37, compared to a current price of ¥95.10 — trading 109.6% above its estimated fair value. The current Accounts Payable is ¥231 Mil. Shanghai Medicilon's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Accounts Payable is ¥231 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued. The current stock price of ¥95.10 is trading 109.6% above its estimated GF Value™ of ¥45.37. GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.

Key valuation signals for SHSE:688202:

  • Accounts Payable: ¥231 Mil
  • GF Value™: ¥45.37 vs. price of ¥95.10 (109.6% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Medicilon Business Description

Address Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
72GF Score

Get the complete analysis for SHSE:688202

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥95.10
Price
¥45.37
GF Value